KENNEWICK, WA / ACCESSWIRE / February 1, 2016
/ Advanced Medical Isotope Corporation ("AMIC") (OTC: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today announced that its Founder, Chairman and CEO co-authored
a recent article published in the January, 2016 issue of the World Council on Isotopes(WCI) Newsletter.
The WCI was founded in 2008 and has a global membership from over 50 countries consisting of 103 member organizations and 40 individual members. WCI provides a
strong voice, as an internationally recognized non-governmental organization, at important regional and international forums. WCI cooperates actively with other regional and international
organizations in the promotion of the peaceful applications of isotope technologies. WCI will host the 9th International Conference on Isotopes in Doha, Qatar in 2017.
The January 2016 WCI Newsletter features an article titled "Special Report on Advances in Medical Radiotherapy". This article was written as an update to the book
"Radiation and Modern Life: Fulfilling Marie Curie's Dream" by Alan E. Waltar published in 2004. The book discusses a wide range of benefits and commercial uses of radioisotopes in 15 chapters
that include titles such as Thriving in Radiation, Harnessing Radiation and Medicine. In his continued commitment to educate others on the beneficial uses of radioisotopes, author Alan E. Waltar
recently combined his latest research with fresh input from medical therapy industry experts to provide information on new and exciting medical radioisotope technologies.
AMIC Founder, Chairman and CEO James C. Katzaroff said "I was honored to be contacted by Dr. Waltar to collaborate on an article highlighting new and promising
radioisotope medical therapies, including AMIC's Y-90 RadioGel(TM) device. It is exciting to have the opportunity to discuss our technology, as well as other new radioisotope therapies in a
publication that is distributed through the World Council on Isotopes."
Dr. Alan E. Waltar recently retired as Director of Nuclear Energy at the Pacific Northwest National Laboratory. He has also served as Professor and Head of the
Nuclear Engineering Department for Texas A&M and President of the American Nuclear Society. Dr. Waltar serves as a consultant to numerous governmental national and international nuclear
organizations as well as several private nuclear firms. He is the Chair of the Scientific Committee for AMIC and his support for AMIC is focused on helping the company meet their goals of
efficient, broad spectrum, radioisotope production.
James C. Katzaroff is the CEO, Chairman and Founder of AMIC. He is a past Vice Chairman of the Fighting Children's Cancer Foundation, a past member of the Life
Sciences Washington Board of Directors, and currently serves as the Vice Chairman of Go-Nuclear, Inc. A strong desire to make an unshakable impact in the fight against cancer led Mr. Katzaroff to
found AMIC in 2006.
The WCI January 2016 Newsletter including the article "Special Report on Advances in Medical Radiotherapy" can be viewed at: http://www.isotopeworld.com/about-us/awards-recognition/
About Advanced Medical Isotope
Advanced Medical Isotope Corporation (ADMD) is a late stage development company engaged in the development of brachytherapy devices for therapeutic applications.
AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products. Brachytherapy uses radiation to destroy cancerous tumors by
placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the
United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please
visit our website, www.isotopeworld.com
Safe Harbor Statement:
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the
use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and
uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, AMIC's ability to successfully
execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of
continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in
customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance
quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's
Advanced Medical Isotope Corporation
James C. Katzaroff, CEO
1021 N. Kellogg St.
Kennewick, WA 99336
Circadian Group Investor Relations
+1 (866) 950-8300
SOURCE: Advanced Medical Isotope